Literature DB >> 1546832

Overnight theophylline concentrations and effects on sleep and lung function in chronic obstructive pulmonary disease.

R J Martin1, J Pak.   

Abstract

Circadian alterations in lung function occur in respiratory disorders, with the nadir during the sleep-related hours. Higher therapeutic serum theophylline concentrations (STC) during the night have been shown to improve lung function in reversible airway disease. To determine what effect higher nocturnal STC would have in patients with chronic obstructive pulmonary disease (COPD) on overnight lung function, oxygen saturation, and sleep quality, two different theophylline products were used to give higher or lower STC during the night. We found that with a higher STC (15.0 +/- 1.0 versus 11.0 +/- 1.0 micrograms/ml, p = 0.005) at 7:00 A.M., the overnight changes in FEV1 (+7.4 +/- 5.7% versus -18.9 +/- 7.9%, respectively) and FVC (+1.8 +/- 7.5% versus -17.2 +/- 3.9%, respectively) were significantly better. However, there was no apparent effect on oxygen saturation (mean sleep values for higher STC were 85.3 +/- 1.2%, and for lower STC they were 86.5 +/- 0.8%). The higher STC did not adversely affect sleep latency, sleep efficiency, or sleep staging. We conclude that a higher therapeutic STC during sleep will improve lung function without altering oxygen saturation in patients with COPD. In this group of patients, the higher STC did not interfere with sleep characteristics.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1546832     DOI: 10.1164/ajrccm/145.3.540

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  11 in total

1.  Sleep and Obstructive Lung Diseases.

Authors:  Michael E Ezzie; Jonathan P Parsons; John G Mastronarde
Journal:  Sleep Med Clin       Date:  2008-12

2.  Chronic respiratory failure in COPD: is there a place for a respiratory stimulant?

Authors:  P A Bardsley
Journal:  Thorax       Date:  1993-08       Impact factor: 9.139

3.  Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease.

Authors:  P M A Calverley; A Lee; L Towse; J van Noord; T J Witek; S Kelsen
Journal:  Thorax       Date:  2003-10       Impact factor: 9.139

4.  Underdiagnosed asthma in South Australia.

Authors:  R J Adams; D H Wilson; S Appleton; A Taylor; E Dal Grande; C R Chittleborough; R E Ruffin
Journal:  Thorax       Date:  2003-10       Impact factor: 9.139

Review 5.  Sleep abnormalities and treatment in emphysema.

Authors:  Samuel Krachman; Omar A Minai; Steven M Scharf
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

Review 6.  Physiological changes due to age. Implications for respiratory drug therapy.

Authors:  J F Morris
Journal:  Drugs Aging       Date:  1994-03       Impact factor: 3.923

Review 7.  Management of insomnia in patients with chronic obstructive pulmonary disease.

Authors:  Charles F P George; Charles D Bayliff
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 8.  Oral theophylline for chronic obstructive pulmonary disease.

Authors:  F S Ram; P W Jones; A A Castro; J A De Brito; A N Atallah; Y Lacasse; R Mazzini; R Goldstein; S Cendon
Journal:  Cochrane Database Syst Rev       Date:  2002

9.  Sleep quality predicts quality of life in chronic obstructive pulmonary disease.

Authors:  Steven M Scharf; Nimrod Maimon; Tzahit Simon-Tuval; Barbara J Bernhard-Scharf; Haim Reuveni; Ariel Tarasiuk
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-12-22

10.  Effect of Triple Therapy with Budesonide-Formoterol-Tiotropium Versus Placebo-Tiotropium on Sleep Quality in Patients with Chronic Obstructive Pulmonary Disease.

Authors:  Samuel L Krachman; Maria Elena Vega; Daohai Yu; Joseph Demidovich; Harsh Patel; Frederic Jaffe; Xavier Soler; Tahseen Shariff; Gilbert E D'Alonzo; Wissam Chatila; Sheila Weaver; Yasmin Daraz; Sydney Cohen; Gerard J Criner
Journal:  Chronic Obstr Pulm Dis       Date:  2021-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.